Clinical trial

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

Name
23-048
Description
This is an individually randomized, controlled, single blind four arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus chloroquine (CQ) (IPT-SPCQ). Arm 3: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ).Arm 4: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.
Trial arms
Trial start
2024-10-01
Estimated PCD
2025-07-01
Trial end
2025-12-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
Dihydroartemisinin-Piperaquine
Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
Arms:
Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP)
Other names:
DP, D-Artepp, DuoCotecxin, Artekin, Eurartesim, Ridmal
Chloroquine
Treatment will be with CQ alone if female and 13 years old or older in all study arms. Treatment in combination with SP in Arm 2 (females less than 13 years old and all males).
Arms:
Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP), Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPT-SPAQ), Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus chloroquine (IPT-SPCQ)
Other names:
Aralen, Hydroxychloroquine, Lariago
Sulfadoxine pyrimethamine
Treatment in combination with CQ in Arm 2 (females less than 13 years old and all males). Treatment in combination with AQ in Arm 3 (females less than 13 years old and all males).
Arms:
Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus chloroquine (IPT-SPCQ)
Other names:
SP
Sulfadoxine-pyrimethamine-amodiaquine
Treatment in Arm 3 (females less than 13 years old and all males).
Arms:
Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPT-SPAQ)
Other names:
SPAQ, SPAQ-Co
Size
1000
Primary endpoint
Number of participants with P. falciparum infection
6-8 weeks after the last intervention
Eligibility criteria
Student Inclusion Criteria: * Currently enrolled in the study school * Plan to attend the study school for the remainder of the school year * Parent/guardian available to provide written informed consent Student Exclusion Criteria: * Current evidence of severe malaria or danger signs * Known adverse reaction to the study drugs * History of cardiac problems or fainting * Taking medications known to prolong QT * Family history of prolonged QT * History of epilepsy or psoriasis * Taking cotrimoxazole for long-term prophylaxis Younger child Inclusion Criteria * Slept in the household for most nights in the last month * Age 6-59 months * Parent/guardian available to provide written informed consent Younger child Exclusion Criteria - Current evidence of severe malaria or danger signs
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Students will be randomized to four arms Arm 1: intermittent preventive treatment with dihydroartemisinin-piperaquine (IPTsc-DP); Arm 2: intermittent preventive treatment with sulfadoxine-pyrimethamine plus chloroquine (IPTsc-SPCQ). Arm 3: intermittent preventive treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPTsc-SPAQ); Arm 4 the control arm. Females 13 years and older (likely post-menarche) in Arms 1, 2 and 3 will receive chloroquine alone.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}}
Updated at
2023-10-16

1 organization

4 products

2 indications

Indication
Malaria
Indication
Anemia